

# Beyond Insulin:

## Innovative research in T1D prevention and cure



AUSTRALASIAN  
TYPE 1 DIABETES  
IMMUNOTHERAPY  
COLLABORATIVE

**Speaker's name:** Dr. Alice Long

**Seminar date:** Thursday, 21<sup>st</sup> November 2024, 1-2pm AEST

**Seminar title:** Clues to how T cell tolerance prevents T1D progression revealed through clinical trials

**Zoom link:** <https://us02web.zoom.us/j/5056623028> **Passcode:** 230004

**About the speaker:** Dr. Alice Long received her BS degree from Macalester College and PhD



in Immunology from Emory University. After post-doctoral studies at the University of California at Davis, she joined a Seattle-based biotechnology company, Xcyte Therapies. In 2005, Dr. Long joined Benaroya Research Institute (BRI). Her lab is focused on discovering how tolerance is lost in human autoimmunity and how therapy can restore tolerance. She approaches these questions with three inter-related projects: 1) Causes and consequences of reduced IL-2 responses, 2) Definition of CD8 T cell exhaustion associated with beneficial disease outcomes and 3) Discovering responder signatures to therapy.

**Brief outline of seminar content:** Type 1 diabetes progression is delayed in some individuals but not others following treatment with immune modulatory therapies. Dr. Alice Long will present the work of her group studying T cell populations that are associated with better response in order to better tailor treatments.

For more information about the seminar series, please contact Michelle So [mso@svi.edu.au](mailto:mso@svi.edu.au)